60 results on '"Lunghi G"'
Search Results
2. SARS-CoV-2 hampers dopamine production in iPSC-derived dopaminergic neurons
3. EILF-Italian migrants study: An HCV and HBV micro elimination pilot project
4. Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan, Lombardy, Italy
5. Safety and efficacy of up to 76 weeks 10 mg/day (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis
6. PIVKA_II a useful biomarker for hepatocellular carcinoma in caucasian HCV cirrhotic patients treated with direct-acting antivirals
7. Chemokine changes during direct antiviral agents (DAA) therapy in patients with HCV infection or reinfection after liver transplantation: preliminary insights on their possible correlates
8. Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis
9. Safety and effectiveness of DAA treatment and clinical outcomes of HCV liver transplanted patients with recurrent hepatitis C infection: a single center 3-year study from Italy
10. Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study
11. Risk and outcome of hepatitis B virus reactivation during chronic hepatitis C treatment with direct-acting antivirals in patients with HCV-related advanced fibrosis: a single-center experience
12. CMV-specific T-cell Response After Lung Transplantation
13. Validation of the EASL 2017 HBV clinical practice guidelines criteria for switching patients long-term treated with Tenofovir difumarate to Entecavir or Tenofovir alafenamide in a real life setting
14. Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: A single-center experience
15. Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment
16. CMV: Reactivation and Prematurely Discontinued Prophylaxis
17. Serum markers for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment
18. Serum Markers for early diagnosis of hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virological response to direct-acting antivirals treatment
19. Acute respiratory distress syndrome in adenovirus type 4 pneumonia: A case report
20. Core Antigen Quantification to Monitor Treatment Efficacy in Patients with Chronic Hepatitis C Receiving Directly Acting Antivirals
21. Cost Analysis of Residual Viremia Detected by Two Real-Time Pcr Assays For Response-Guided (Dual Or Triple) Therapy of Hcv Genotype 1 Infection
22. Comparative evaluation of the new xTAG GPP multiplex assay in the laboratory diagnosis of acute gastroenteritis. Clinical assessment and potential application from a multicentre Italian study
23. Hepatitis Delta prevalence and clinical expression in an immigrant population in Italy
24. Optic neuritis associated with influenza B virus meningoencephalitis
25. 756 SERUM HBsAg DECLINE IS FASTER THAN PREVIOUSLY ESTIMATED IN LONG-TERM NUC RESPONDERS WITH LOW TREATMENT-INDUCED HBsAg LEVELS
26. 755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS
27. T-17 Add-on Peg-IFN improves HBsAg kinetics in HBeAg-negative patients long-term fully suppressed by nucleos(t)ide analogs
28. F-17 Serum HBsAg decline is faster than previously estimated in long-term NUC responders with low treatment-induced HBsAg levels
29. T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC
30. 522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY
31. P.15.2 ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT
32. T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment
33. Fulminant Multiorgan Failure Due to Varicella Zoster Virus and HHV6 in an Immunocompetent Adult Patient, and Anhepatia
34. OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCE
35. 753 NUCLEOS(T)IDE ANALOGUES CAN BE SAFELY DISCONTINUED IN CHRONIC HEPATITIS B PATIENTS ACHIEVING HBSAG SEROCLEARANCE
36. F-34 Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: The Italian multicenter experience
37. F-35 Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance
38. 1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS
39. OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS
40. F.N.16 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS
41. 912 PROGRESSIVE DECLINE OF HBsAg TITERS IN LONG- TERM VIROLOGICAL RESPONDERS TO NUCLEOS(T)IDE ANALOGUE THERAPY FOR CHRONIC HEPATITIS B
42. 916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY
43. [57] 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS
44. 3 years of adefovir and lamivudine combination therapy minimizes the risk of genotypic resistance to ADV in lamivudine resistant patients
45. O.049 Five years of sequential LAM to LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma
46. Natural History of Hepatitis C Virus Infection in Adult Renal Graft Recipients
47. 448 Rescue treatment with adefovir dipivoxil in lamivudine resistant patients with chronic hepatitis B
48. 44 The long-term outcome of HBeAg-Negative patients with cirrhosis treated with lamivudine monotherapy: A 5-year prospective cohort study
49. Genotypic analysis of YMDD locus of HBV in patients responding to lamivudine monotherapy
50. Viral kinetics in hbeag positive and negative patients with HBV-related cirrhosis treated long-term with lamivudine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.